权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Immunology

免疫学

基本信息

批准号：
10115694
负责人：
Jose R Conejo-Garcia
金额：
$ 5.68万
依托单位：
H. LEE MOFFITT CANCER CTR & RES INST
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-02-18 至 2022-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10115694
关键词：
Address Adoptive Cell Transfers Adoptive Transfer Agreement Allogenic Antitumor Response Area Cancer Center Cancer Center Support Grant Cancer Patient Cell Therapy Cells Clinical Clinical Immunology Clinical Services Clinical Trials Collaborations Core Facility Cytotoxic T-Lymphocytes Effector Cell Faculty Funding Gene Expression Profile Goals Grant Hematologic Neoplasms Hematopoietic Neoplasms Histone Deacetylase Inhibitor Human Immune Immune checkpoint inhibitor Immune response Immune system Immunology Immunotherapeutic agent Immunotherapy Industry Infrastructure Interleukin-12 Interruption Intervention Intervention Trial Investments JAK2 gene Laboratory Study Malignant Neoplasms Minor Histocompatibility Antigens Molecular Myeloid-derived suppressor cells NCI-Designated Cancer Center Natural Immunity Natural Killer Cells Patients Peer Review Process Publications Publishing Regulatory T-Lymphocyte Reporting Research Research Personnel Role STAT3 gene Scientist Severities Severity of illness Solid Neoplasm Source T cell response T cell therapy T-Lymphocyte Therapeutic Translating Translations Transplantation Tumor Immunity Tumor-Infiltrating Lymphocytes Vaccination adaptive immunity bench to bedside cancer immunotherapy cohesion cost disorder prevention graft vs host disease graft vs leukemia effect hematopoietic cell transplantation immunoregulation immunotherapy clinical trials immunotherapy trials improved innovation instructor inter-institutional interleukin 9 receptor interleukin-23 leukemia member neoplastic cell novel preclinical study preservation prevent programs recruit response restoration small molecule success tumor working group

项目摘要

PROJECT SUMMARY The overall goal of the Moffitt Cancer Center (MCC) Immunology (IMM) Program is to define the mechanisms by which tumors evade rejection by the immune system and to develop strategies to thwart them. Fundamental discoveries by IMM members have led to novel immunotherapy trials that directly benefit cancer patients. Key to the Program's success is the close integration of IMM clinical, translational, and basic scientists that facilitates rapid progression of novel immunotherapies from the bench to bedside. The goals of Specific Aim 1 are to advance and translate T-cell therapies for solid tumors and hematologic malignancies, by bringing laboratory and pre-clinical studies of the IMM Program to the patient bedside in the form of novel investigator- initiated clinical trials. Specific areas of focus include: (1) adoptive T-cell immunotherapy using ex vivo expanded tumor-infiltrating lymphocytes and genetically modified immune effector cells; (2) mechanistic strategies to improve adoptive cell therapy; (3) restoration of tumor-specific responses by immune checkpoint inhibitors, histone deacetylase inhibitors (HDACi), and vaccination; and (4) defining gene expression signatures of immune responders. MCC infrastructure that supports IMM members includes: (i) the Immunotherapy Working Group that conceives interventional trials; (ii) a Good Manufacturing Practice- compliant Cellular Therapy Core Facility; and (iii) the interdisciplinary Immune and Cellular Therapy clinical service to deliver therapy to patients. The goals of Specific Aim 2 are to define molecular and cellular mechanisms that can exploit innate and adaptive immunity against cancer. Here, IMM members seek to discover and develop molecular approaches to harness the immune system. Collaborative studies include those assessing T-cell recruitment and suppression, natural killer cell control, myeloid-derived suppressor cell expansion, and selective HDACi immune modulation. These initiatives have generated several innovative approaches that control these processes, including therapeutic translation into clinical trials. The goals of Specific Aim 3 are to prevent graft-versus-host disease (GVHD) while maintaining the potency of graft-versus- leukemia and other blood cancers following hematopoietic cell transplantation (HCT). The IMM Program has made significant impact in this arena, including the discovery that Th17 cells have a central role in the severity of GVHD and in the response to therapy. The approaches to prevent GVHD and maintain anti-tumor response include: (1) adoptive transfer of donor Tregs specific against host minor-histocompatibility antigens; (2) targeting the common IL-12/IL-23 p40 receptor chain; (3) targeting JAK2 or STAT3; and (4) defining gene expression signatures associated with operational tolerance following allogeneic HCT. The Program is composed of 25 members from 10 different academic departments. During the reporting period, 534 cancer- related articles were published, with 167 (31)% intra-programmatic and 207 (39%) inter-programmatic. Grant funding for the Program is $18.8 million, of which $7.0 million is peer-reviewed , including 43% from NCI.

项目总结